Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026

FDA's week of January 24–31 delivered 35 regulatory actions across food, devices, pharmaceuticals, and supplements — dominated by 22 food and product recalls, an unusual cluster of four Foreign Supplier Verification Program (FSVP) warning letters issued on a single day, and a warning letter targeting a widely-used blood lead testing device over failures that produced patient false positives.

By the Numbers

Metric	Count
Total items (Jan 24–31)	35
Recalls	22
Warning letters	8
Administrative notices	5
FSVP warning letters (Jan 27)	4
CGMP/QSR warning letters	4
Class I recalls	3
Class II recalls	7
Allergen/labeling-related recalls	~12

---

Lead Story: FDA Flags Flawed Blood Lead Test Used in Pediatric Clinics

The week's most consequential action arrived quietly in the form of a CGMP/Quality System Regulation warning letter to Meridian Bioscience, Inc. and its subsidiary Magellan Diagnostics, Inc., issued January 27 for systemic failures at the company that makes the LeadCare II blood lead testing system. (Source)

LeadCare II is one of the most widely deployed point-of-care blood lead tests in the U.S., used in pediatric clinics, community health centers, and schools to screen children for lead exposure. The FDA's warning letter — stemming from an inspection dated December 22, 2025 — identified failures across virtually every major pillar of the Quality System Regulation (21 CFR Part 820):

• CAPA failures: The company did not properly implement corrective and preventive actions, including in response to known patient false positives.
• Design control failures: Gaps in design verification and validation allowed the deficiencies to persist without adequate engineering review.
• Process validation: Critical manufacturing processes were not fully validated.
• Incoming acceptance: Incoming components lacked proper testing protocols.
• MDR failures: The company violated Medical Device Reporting requirements (21 CFR Part 803) and Corrections and Removals reporting (21 CFR Part 806).

The FDA's letter is unusually demanding: it requires Meridian to retain an outside expert to conduct an audit of the QSR compliance program, with initial certifications due by July 31, 2026 — a hard deadline that will be tracked.

Why this matters beyond one company: false positive blood lead results can trigger unnecessary chelation therapy, a treatment with its own health risks, particularly in children. The LeadCare II is positioned as a screening tool in settings that serve vulnerable populations. When that tool produces unreliable results and the manufacturer isn't fixing the problem, the downstream consequences fall on patients and clinicians who have no visibility into the quality failures upstream.

Manufacturers of Class II point-of-care diagnostics should treat this letter as a template for what FDA expects: CAPA programs that close the loop, MDR filings that capture adverse events accurately, and design controls that don't tolerate ambiguity on devices where false results have clinical consequences.

---

Key Developments

Four FSVP Warning Letters in One Day Signals Escalating Import Scrutiny

On January 27, FDA issued four warning letters to food importers for failing to establish Foreign Supplier Verification Programs (FSVP) — all on the same day:

• American Food Distributor Inc. (inspected July 2025): No FSVP for tahina, extra virgin olive oil, and mallow leaves. (Source)
• MG GROUP USA: No FSVP for White Truffle Olive Oil and fresh truffles. (Source)
• Asli Foods, Inc. (inspected November 2025): No FSVP for Prince Chocolate, Herbal Tea, and Malka Mix Afghani Seekh Kabab. (Source)
• Zip Foods Importers, Inc.: No FSVP for a broad range including Millet Seed, Buckwheat, mushrooms, stone fruits, snack foods, and cheese. (Source)

The consequence for non-compliance is import detention without physical examination (DWPE) under Import Alert #99-41, meaning future shipments can be blocked at the border without individual review. Four letters in one day is not a coincidence — FDA has been working through a backlog of FSVP inspections from late 2025. Specialty food importers and distributors bringing in ethnic foods, gourmet ingredients, and artisanal products should treat FSVP as mandatory infrastructure, not optional paperwork. The regulation (21 CFR Part 1, Subpart L) has been in effect since 2017; enforcement is now catching up.

Honey Product Spiked with Prescription Erectile Dysfunction Drug

Akkarco LLC recalled its "Ashfiat Alharamain Energy Support" honey product after FDA testing revealed undeclared tadalafil — a prescription drug used to treat erectile dysfunction and pulmonary arterial hypertension. The product was distributed nationwide. (Source)

Tadalafil in an undisclosed honey supplement is not a labeling problem — it's an unapproved new drug. Consumers taking nitrates for heart conditions or blood pressure medications face the risk of a dangerous, potentially life-threatening drop in blood pressure. This is a Class I-level risk profile regardless of recall classification assigned.

This type of violation — hidden active pharmaceutical ingredients in honey and "energy support" products marketed with vague health claims — is a known pattern. FDA has cited similar products repeatedly. The supplement category remains a high-risk area for adulteration, and this week's action is a reminder that "natural" and "honey-based" do not immunize products from enforcement.

Wholesale Distributor Recalls All Human Food After Rodent Exposure

Gold Star Distribution Inc. issued a sweeping recall covering all human food products distributed from its facility — spanning snack foods, candy, cooking oil, canned goods, dietary supplements, peanut butter, baby food, and more — due to potential exposure to rodents and rodent activity in its distribution center.

The Class II recall is ongoing. The breadth of product types makes this difficult for consumers to track: there is no single UPC or lot code, only the facility itself. Retailers that received product from Gold Star Distribution should treat the recall as facility-wide.

Gerber Arrowroot Biscuits: Foreign Material from Supplier

Gerber Products Company voluntarily recalled specific batches of its Arrowroot Biscuits (5.5 oz) — a product marketed for infants — due to the potential presence of soft plastic and/or paper pieces originating from a supplier of arrowroot flour. Affected batches were produced between July and September 2025. No injuries have been reported. (Source)

This is a supply chain contamination event, not a Gerber manufacturing failure — but in the infant food category, the distinction matters less than the response. Gerber moved quickly once its supplier issued a recall, which is the correct protocol. Companies sourcing any ingredient from third-party suppliers should have procedures in place to act on supplier-initiated recalls within days.

Food Color Additive Labeling: A Cluster of Recalls

Five recalls this week shared the same root cause: undeclared FD&C synthetic color additives that must be individually declared on food labels under 21 CFR Part 101. The affected products were all from small or regional producers:

• Gaceniga Authentic Cuban Loaf Cake Classic (24 oz) — CATAO MARKET LLC
• Mini Gaceniga Authentic Cuban Loaf Cake Classic (12 oz) — CATAO MARKET LLC
• Gaceniga Authentic Cuban Loaf Cake Raisins (24 oz) — CATAO MARKET LLC
• Mini Gaceniga Authentic Cuban Loaf Cake Raisins (12 oz) — CATAO MARKET LLC
• Cuban Crackers Galletas Cubanas (8 oz) — Lily's Bakery Factory / Best Floridian, LLC — undeclared FD&C Yellow #5, Yellow #6, and Red 40

All five were Class II recalls. The color additive labeling requirement under 21 CFR §101.22 is unambiguous: each artificial color must be named on the label. Small bakeries and food manufacturers selling through retail often lack the regulatory support to catch these requirements. But "small" does not mean exempt — and FD&C Yellow #5 (tartrazine) triggers allergic reactions in sensitive individuals, including people with aspirin hypersensitivity.

---

The Bigger Picture

This week's recall mix reflects a persistent structural problem in the food supply: allergen and labeling compliance failures at small and mid-size manufacturers. Twelve of the 22 recalls this week involved undeclared allergens or mislabeled additives — a ratio that tracks with longer-term trends in the Policy Canary database, where allergen-related recalls have been a leading driver across all 75-day rolling periods.

Over the past 75 days tracked in our system, FDA has processed 525 total regulatory actions, including 227 recalls and 119 warning letters. CGMP violations account for 100 of those actions — the second-largest category after recalls. The FSVP enforcement batch this week fits a pattern where FDA's inspection pipeline from late 2024 and 2025 is now translating into published enforcement letters, roughly 3–6 months after inspections occurred.

The Meridian Bioscience warning letter is a reminder that device companies are not exempt from the same CGMP accountability applied to drug manufacturers. With 26 Class II device enforcement actions in the 75-day window and 19 Class III device actions, medical device quality system enforcement continues to run at meaningful volume.

---

What to Watch

• July 31, 2026: Meridian Bioscience/Magellan Diagnostics must submit initial certifications from an outside QSR compliance auditor. This is an unusual and hard deadline — watch for updates.
• March 30, 2026: Comment deadlines close on multiple FDA Federal Register notices published Jan 27, including proposed collection of information on Medication Guides for prescription drugs, and several patent extension determinations for recently approved products (BIMZELX, TRYVIO, RYZNEUTA, IMAAVY, REZDIFFRA, EXBLIFEP).
• FDA Rare Disease Innovation Hub RFI: A January 30 Federal Register notice invites public comments on future programming for the hub. Organizations active in rare disease drug development should engage. (Source)
• FSVP sweep: The four January 27 letters likely represent the first of several batches. Importers in the specialty food, ethnic food, and gourmet ingredient sectors should review their FSVP documentation now.

---

Policy Canary monitors FDA changes for your specific products — by name, by ingredient, by category. If your business touches food, supplements, devices, or drugs regulated by FDA, we track the enforcement signals that matter to you. Join the pilot program